B&L Retisert Drug Delivery Implant FDA Filing Delayed By One Year
This article was originally published in The Gray Sheet
Bausch & Lomb will wait for results from its second pivotal trial for the Retisert drug-delivery implant for treating posterior uveitis before submitting a new drug application to FDA, which is expected in mid-2004
You may also be interested in...
Bausch & Lomb continues to transform itself into a drug-delivery eyecare company from a traditional contact lens firm, with implants and molecular compounds in various stages of development
Liquid biopsy start-up Grail Inc. announced that a study of almost 6,700 participants found that its blood test could detect more than 50 types of cancer with a low false-positive rate. See what Minetta Liu, study co-lead author and a Mayo Clinic professor of oncology, had to say about the research.